Overview
- Shares rose 24.7% on listing day, valuing the company at about HK$16.7 billion after raising roughly HK$2.3 billion in the IPO.
- Proceeds will support clinical-stage drug programs, development of new generative AI models and expansion of a robotic laboratory.
- First-half 2025 revenue fell 54% to $27.5 million, with 87% from licensing and 7% from AI software, and the company reported a $19.2 million net loss versus an $8 million profit a year earlier.
- Insilico is training its Pharma.AI platform, described by the founder as a “digital Einstein,” and plans to widen access to some AI tools in three to five years, potentially via low-cost subscriptions.
- The company is expanding its research base in China and has struck deals including licenses with Exelixis and Menarini worth up to $2.1 billion in milestones, a new partnership with Eli Lilly exceeding $100 million and a recent anemia candidate license to Taigen Biotechnology.